CoChat

Retinoids in cancer therapy and chemoprevention: promise meets resistance

The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.

Abstract

Retinoids (natural and synthetic derivatives of vitamin A) signal potent differentiation and growth-suppressive effects in diverse normal, premalignant, and malignant cells. A strong rationale exists for the use of retinoids in cancer treatment and chemoprevention based on preclinical, epidemiological, and early clinical findings. Despite the success of all-trans-retinoic acid (RA)-based differentiation therapy in acute promyelocytic leukemia (APL), the broad promise of retinoids in the clinic has not yet been realized. In addition to the expected limited activity of any single therapeutic agent, translation of retinoid activities from the laboratory to the clinic has met with intrinsic or acquired retinoid resistance. Evidence suggests that solid tumors develop intrinsic resistance to retinoids during carcinogenesis. In contrast, relapse of APL is often associated with acquired resistance to retinoid maturation induction. This review discusses what is known about retinoid resistance mechanisms in cancer therapy and chemoprevention. Strategies to overcome this resistance will be discussed, including combination therapy with other differentiation-inducing, cytotoxic or chromatin-remodeling agents, as well as the use of receptor-selective and nonclassical retinoids. Opportunities exist in the post-genomic era to bypass resistance to classical retinoids by identifying target genes and associated pathways that directly mediate the antineoplastic effects of retinoids. In this rega…

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1206936

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 126 references

Research works printed but not linked: 1

  1. He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr RP, Rifkind RA, Marks PA, Richon VM and Pandolfi PP . (2001). J. Clin. Invest., 108, 1321–1330. · doi:10.1172/jci200111537 · Paper page

Cited by

See all 355

Metadata

Authors
Freemantle, S. J., Spinella, M. J., & Dmitrovsky, E.
Affiliations
Dartmouth College (US)
Corresponding author
Freemantle, Sarah J
Venue
Oncogene
Published
2003-10-20
Volume
22
Issue
47
Pages
7305-7315
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2040347441
Cited by
312
References
121
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 7 · 2022: 9 · 2021: 8 · 2020: 11 · 2019: 9 · 2018: 4 · 2017: 11 · 2016: 19 · 2015: 16 · 2014: 11 · 2013: 10 · 2012: 13
FWCI
1.53
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (7k01ca075154-02)
  • National Cancer Institute (R0-1 CA87546, R01-CA62275, R01CA062275, K01 CA 75154-01, R01CA087546)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Keywords
retinoids, vitamin A derivatives, retinoid resistance, chemoprevention, cancer therapy, differentiation therapy, all-trans retinoic acid, acute promyelocytic leukemia, relapse, combination therapy, chromatin remodeling, antineoplastic mechanism, carcinogenesis
MeSH terms
Humans, Neoplasms, Retinoids, Leukemia, Promyelocytic, Acute, Receptors, Retinoic Acid, Drug Resistance, Neoplasm, Tumor Suppressor Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Retinoids in cancer therapy and chemoprevention: promise meets resistance. https://app.cochat.ai/papers/10.1038/sj.onc.1206936
The paper
Freemantle, S. J., Spinella, M. J., & Dmitrovsky, E. (2003). Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. https://doi.org/10.1038/sj.onc.1206936

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.